Chronic Myeloid Leukaemia and the Imatinib Revolution

One chromosome, one broken switch

Nearly every case of CML traces back to a single genetic accident. In a blood stem cell, a piece of chromosome 9 swaps places with a piece of chromosome 22 — a reciprocal translocation written t(9;22). The shortened chromosome 22 that results is the famous Philadelphia chromosome (named for the city where it was discovered). This swap fuses two genes that should never meet: ABL from chromosome 9 and BCR from chromosome 22. The fusion gene, BCR-ABL, codes for a single hybrid protein — and that protein is the whole disease.

Normal ABL is a tyrosine kinase — an enzyme that adds phosphate groups to other proteins to pass along growth signals. Crucially, it is normally switched ON only when the cell needs it and switched OFF the rest of the time. Fused to BCR, that off-switch is broken. BCR-ABL is a constitutively active tyrosine kinase: permanently on, relentlessly firing the signals that tell the cell to divide and to resist dying. The bone marrow floods the blood with white cells. There is no external growth factor driving it, no toxin — just one enzyme jammed in the on position.

The key in the lock: how imatinib works

A tyrosine kinase needs fuel to fire: it grabs a molecule of ATP and transfers its phosphate onto a target protein. That means every kinase has an ATP-binding pocket. Imatinib is a small molecule shaped to slide into the ATP-binding pocket of BCR-ABL and sit there. With the pocket blocked, no ATP can bind, no phosphate is transferred, and the kinase falls silent. The signal to proliferate stops; the malignant clone loses its drive and dies back. This is the entire logic of a tyrosine kinase inhibitor (TKI): don't poison the cell — unplug its broken switch.

But how do you know the pill is working? You don't just watch the white-cell count — you measure the enemy directly. Because BCR-ABL is a unique fusion, its messenger RNA can be counted with exquisite sensitivity by quantitative PCR. The BCR-ABL transcript level tells you how much disease remains. A falling transcript is a molecular response; a deep, sustained drop (often reported on an international scale) is the treatment goal. Monitoring is molecular, not just morphological — you track the very molecule the drug was built to hit.

When the key stops fitting: resistance and newer TKIs

Sometimes the disease that responded beautifully starts to return, or never responded well from the start. The commonest reason is a mutation in the kinase domain of BCR-ABL — a small change in the shape of the ATP pocket so that imatinib no longer fits snugly. The lock changed, and the old key slips. This is not a failure of the concept; it is the tumour evolving. The answer was to build better keys.

A targeted drug, but not a free one: tolerability

Because TKIs spare the rest of the body far more than classical chemotherapy, they are generally well tolerated and taken for years. But "targeted" is not "side-effect-free". Imatinib commonly causes fluid retention (puffiness, periorbital oedema), cytopenias (low blood counts, since normal marrow shares the pathway), nausea and other GI upset, muscle cramps and rash. The newer agents add their own drug-specific signatures — dasatinib is associated with pleural effusions, while nilotinib and ponatinib carry cardiovascular and vascular-occlusive risks. Choice of TKI is therefore matched to the patient's other conditions.

Two practical points decide whether the pill keeps working. First, adherence: these are oral drugs taken at home, indefinitely, and skipped doses are a leading cause of lost molecular response — the kinase simply switches back on between doses. Second, drug interactions: imatinib and its cousins are metabolized by the liver enzyme CYP3A4, so strong CYP3A4 inhibitors (like certain antifungals) can raise levels and toxicity, while inducers (like rifampicin) can drop levels below the effective range. A careful medication and even grapefruit-juice history matters.